  A high body mass index ( BMI) is associated with increased cardiovascular risk. We sought to identify whether BMI influences the choice of lipid-lowering treatment in a large , real-world cohort of 52916 patients treated with statins. The Dyslipidemia International Study ( DYSIS) is a cross-sectional , observational , multicentre study in statin-treated patients â‰¥ 45 years of age from 30 countries; 1.1 % were underweight ( BMI < 18.5 kg/m